Biosynth, a supplier of raw materials to the life sciences industry, recently acquired Celares, a developer and manufacturer of bioconjugate drugs, conjugate vaccines, activated PEGs and polymer-based drug delivery excipients.   With this acquisition Biosynth aims to strengthen its exposure to that fast-growing bioconjugate and conjugate vaccines markets. This expands the company’s capabilities and enables Biosynth to offer the bioconjugation of antibodies, antigens and peptides to existing ph...